{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:12:05Z","timestamp":1760296325514,"version":"build-2065373602"},"reference-count":98,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2010,10,4]],"date-time":"2010-10-04T00:00:00Z","timestamp":1286150400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2011,2,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Philadelphia chromosome (Ph)\u2010negative myeloproliferative neoplasms (MPNs) are characterized by stem cell\u2010derived, unrestrained clonal myeloproliferation. The World Health Organization classification system, proposed in 2008, identifies 7 distinct categories of Ph\u2010negative MPNs including essential thrombocythemia (ET); polycythemia vera (PV); primary myelofibrosis (PMF); mastocytosis; chronic eosinophilic leukemia; chronic neutrophilic leukemia; and MPN, unclassifiable. For many years, the treatment of ET, PV, and PMF, the most frequently diagnosed Ph\u2010negative MPNs, has been largely supportive. In recent years, that paradigm has been challenged because of the discovery of a recurrent point mutation in the Janus kinase 2 (<jats:italic>JAK2<\/jats:italic>) gene (<jats:italic>JAK2<\/jats:italic><jats:sup><jats:italic>V617F<\/jats:italic><\/jats:sup>). This mutation can be detected in the vast majority of patients with PV and approximately half of patients with ET or PMF and serves as both a diagnostic marker as well as representing a putative molecular target for drug development. Several putative targeted agents with significant in vitro JAK2 inhibitory activity and various degrees of JAK2 specificity are currently undergoing clinical evaluation. Furthermore, other investigational non\u2010tyrosine kinase inhibitor approaches such as immunomodulatory agents and pegylated interferon\u2010\u03b1 have also shown promising results in MPNs. Cancer 2011. \u00a9 2010 American Cancer Society.<\/jats:p>","DOI":"10.1002\/cncr.25672","type":"journal-article","created":{"date-parts":[[2010,10,4]],"date-time":"2010-10-04T17:16:37Z","timestamp":1286212597000},"page":"662-676","source":"Crossref","is-referenced-by-count":16,"title":["Experimental therapeutics for patients with myeloproliferative neoplasias"],"prefix":"10.1002","volume":"117","author":[{"given":"Meetu","family":"Agrawal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravin J.","family":"Garg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Quintas\u2010Cardama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,10,4]]},"reference":[{"key":"e_1_2_9_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-077966"},{"key":"e_1_2_9_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404955"},{"key":"e_1_2_9_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V6.4.372.372"},{"key":"e_1_2_9_5_2","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1182\/blood.V83.3.744.744","article-title":"Identification of masked polycythemia vera from patients with idiopathic marked thrombocytosis by endogenous erythroid colony assay","volume":"83","author":"Shih LY","year":"1994","journal-title":"Blood."},{"key":"e_1_2_9_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03688.x"},{"key":"e_1_2_9_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-196206000-00001"},{"key":"e_1_2_9_8_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-57-1-73"},{"key":"e_1_2_9_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-12-128454"},{"key":"e_1_2_9_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03386.x"},{"key":"e_1_2_9_11_2","first-page":"144","article-title":"Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and second hematologic malignancies","volume":"23","author":"Ellis JT","year":"1986","journal-title":"Semin Hematol."},{"key":"e_1_2_9_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.03.023"},{"key":"e_1_2_9_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature03546"},{"key":"e_1_2_9_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)71142-9"},{"key":"e_1_2_9_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051113"},{"key":"e_1_2_9_16_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C500138200"},{"key":"e_1_2_9_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67785-9"},{"key":"e_1_2_9_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404908"},{"key":"e_1_2_9_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra063728"},{"key":"e_1_2_9_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-05-091850"},{"key":"e_1_2_9_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-008805"},{"key":"e_1_2_9_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2008.05.006"},{"key":"e_1_2_9_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.233"},{"key":"e_1_2_9_24_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-12-064287"},{"key":"e_1_2_9_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81167-8"},{"key":"e_1_2_9_26_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-03-0885"},{"key":"e_1_2_9_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.6896"},{"key":"e_1_2_9_28_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-12-4852"},{"key":"e_1_2_9_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1183"},{"key":"e_1_2_9_30_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0509714102"},{"key":"e_1_2_9_31_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0000018"},{"key":"e_1_2_9_32_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1071545"},{"key":"e_1_2_9_33_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-12-062125"},{"key":"e_1_2_9_34_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-009514"},{"key":"e_1_2_9_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065202"},{"key":"e_1_2_9_36_2","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1182\/blood-2007-07-101576","article-title":"Somatic mutations of JAK2 exon 12 in patients with JAK2(V617F) negative myeloproliferative disorders","volume":"111","author":"Pietra D","year":"2008","journal-title":"Blood."},{"key":"e_1_2_9_37_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-018879"},{"key":"e_1_2_9_38_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030270"},{"key":"e_1_2_9_39_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-05-089003"},{"key":"e_1_2_9_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06430.x"},{"key":"e_1_2_9_41_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-939441"},{"key":"e_1_2_9_42_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.9.3370"},{"key":"e_1_2_9_43_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199504273321704"},{"key":"e_1_2_9_44_2","first-page":"1","article-title":"Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia","volume":"16","author":"Squizzato A","year":"2008","journal-title":"Cochrane Database Syst Rev."},{"key":"e_1_2_9_45_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043800"},{"key":"e_1_2_9_46_2","first-page":"334","article-title":"The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era","volume":"7","author":"Zhan H","year":"2009","journal-title":"Clin Adv Hematol Oncol."},{"key":"e_1_2_9_47_2","first-page":"215","article-title":"Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation","volume":"89","author":"Barbui T","year":"2004","journal-title":"Hematologica."},{"key":"e_1_2_9_48_2","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.188"},{"key":"e_1_2_9_49_2","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2010.14"},{"key":"e_1_2_9_50_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-234880"},{"key":"e_1_2_9_51_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2405080"},{"key":"e_1_2_9_52_2","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2004-5-12-253"},{"key":"e_1_2_9_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcdb.2008.07.002"},{"key":"e_1_2_9_54_2","first-page":"1347","article-title":"JAK2, a third member of the JAK family of protein tyrosine kinases","volume":"7","author":"Harpur AG","year":"1992","journal-title":"Oncogene."},{"key":"e_1_2_9_55_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M205156200"},{"key":"e_1_2_9_56_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-214957"},{"key":"e_1_2_9_57_2","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.V114.22.756.756","article-title":"Long\u2010term follow\u2010up and optimized dosing regimen of INCB018424 in patients with myelofibrosis: durable clinical, functional and symptomatic responses with improved hematological safety [abstract]. ASH Annual Meeting Abstracts.","volume":"114","author":"Verstovsek S","year":"2009","journal-title":"Blood"},{"key":"e_1_2_9_58_2","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1182\/blood.V112.11.2804.2804","article-title":"The clinical phenotype of myelofibrosis encompasses a chronic inflammatory state that is favorably altered by INCB018424, a selective inhibitor of JAK1\/2 [abstract]. ASH Annual Meeting Abstracts","volume":"112","author":"Tefferi A","year":"2008","journal-title":"Blood"},{"key":"e_1_2_9_59_2","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1182\/blood.V114.22.3917.3917","article-title":"Validation of the serial use of the myelofibrosis symptom assessment form (MF\u2010SAF) for measuring symptomatic improvement: performance in 86 myelofibrosis patients on INCB018424 clinical trial [abstract]. ASH Annual Meeting Abstracts.","volume":"114","author":"Mesa RA","year":"2009","journal-title":"Blood"},{"key":"e_1_2_9_60_2","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1182\/blood.V112.11.2802.2802","article-title":"Characterization of JAK2 V617F allele burden in advanced myelofibrosis (MF) patients: no change in V617F:WT JAK2 ratio in patients with high allele burdens despite profound clinical improvement following treatment with JAK inhibitor, INCB018424 [abstract]. ASH Annual Meeting Abstracts","volume":"112","author":"Verstovsek S","year":"2008","journal-title":"Blood"},{"key":"e_1_2_9_61_2","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1182\/blood.V114.22.311.311","article-title":"A phase 2 study of INCB018424, an oral, selective JAK1\/JAK2 inhibitor, in patients with advanced polycythemia vera and essential thrombocythemia refractory to hydroxyurea [abstract]. ASH Annual Meeting Abstracts","volume":"114","author":"Verstovsek S","year":"2009","journal-title":"Blood"},{"key":"e_1_2_9_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2008.02.009"},{"key":"e_1_2_9_63_2","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1182\/blood.V114.22.755.755","article-title":"A phase I study of TG101348, a selective JAK2 inhibitor, in myelofibrosis: clinical response is accompanied by significant reduction in JAK2V617F allele burden [abstract]. ASH Annual Meeting Abstracts","volume":"114","author":"Pardanani AD","year":"2009","journal-title":"Blood"},{"key":"e_1_2_9_64_2","first-page":"2008","article-title":"A phase I study of XL019, a selective JAK2 inhibitor, in patients with polycythemia vera [abstract]. ASH Annual Meeting Abstracts","volume":"112","author":"Paquette R","journal-title":"Blood"},{"key":"e_1_2_9_65_2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1182\/blood.V112.11.98.98","article-title":"A phase I study of XL019, a selective JAK2 inhibitor, in patients with primary myelofibrosis, post\u2010polycythemia vera, or post\u2010essential thrombocythemia myelofibrosis [abstract]. ASH Annual Meeting Abstracts","volume":"112","author":"Shah NP","year":"2008","journal-title":"Blood"},{"key":"e_1_2_9_66_2","doi-asserted-by":"publisher","DOI":"10.1586\/era.09.14"},{"key":"e_1_2_9_67_2","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1182\/blood.V106.11.403.403","article-title":"A randomized open label study of lestaurtinib (CEP\u2010701), an oral FLT3 inhibitor, administered in sequence with chemotherapy in patients with relapsed AML harboring FLT3 activating mutations: clinical response correlates with successful FLT3 inhibition [abstract]. ASH Annual Meeting Abstracts","volume":"106","author":"Levis M","year":"2005","journal-title":"Blood"},{"key":"e_1_2_9_68_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-04-083402"},{"key":"e_1_2_9_69_2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1182\/blood.V112.11.99.99","article-title":"An open label study of CEP\u2010701 in patients with JAK2V617F positive polycythemia vera and essential thrombocytosis [abstract]. ASH Annual Meeting Abstracts.","volume":"112","author":"Moliterno AR","year":"2008","journal-title":"Blood"},{"key":"e_1_2_9_70_2","first-page":"3543","article-title":"Phase II study of CEP701 an orally available JAK2 inhibitor in patients with primary myelofibrosis and post polycythemia vera\/essential thrombocythemia myelofibrosis [abstract]","volume":"110","author":"Verstovsek S","year":"2007","journal-title":"ASH Annual Meeting Abstracts. Blood"},{"key":"e_1_2_9_71_2","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V114.22.754.754","article-title":"A multicenter, open label Phase I\/II study of CEP701 (Lestaurtinib) in adults with myelofibrosis; a report on phase I: a study of the myeloproliferative disorders research consortium [abstract]. ASH Annual Meeting Abstracts","volume":"114","author":"Hexner E","year":"2009","journal-title":"Blood"},{"key":"e_1_2_9_72_2","first-page":"538","article-title":"SB1518: a potent and orally active JAK2 inhibitor for the treatment of myeloproliferative disorders [abstract]","volume":"110","author":"Goh KC","year":"2007","journal-title":"ASH Annual Meeting Abstracts. Blood"},{"key":"e_1_2_9_73_2","first-page":"3905","article-title":"Phase I dose\u2010escalation trial of SB1518, a novel JAK2\/FLT3 inhibitor, in acute and chronic myeloid diseases, including primary or post\u2010essential thrombocythemia\/polycythemia vera myelofibrosis [abstract]","volume":"114","author":"Verstovsek S","year":"2009","journal-title":"ASH Annual Meeting Abstracts. Blood"},{"key":"e_1_2_9_74_2","first-page":"4907","article-title":"The Jak2\u2010Inhibitor AG490 affects survival of BFU\u2010E and CFU\u2010GM of myeloproliferative disorder cells carrying the JAK2 V617F mutation [abstract]","volume":"108","author":"Duek A","year":"2006","journal-title":"ASH Annual Meeting Abstracts. Blood"},{"key":"e_1_2_9_75_2","first-page":"557","article-title":"A selective and potent oral inhibitor of the JAK2 tyrosine kinase reverses polycythemia and leukocytosis induced by JAK2 V617F in a mouse model [abstract]","volume":"110","author":"Zaleskas V","year":"2007","journal-title":"ASH Annual Meeting Abstracts. Blood"},{"key":"e_1_2_9_76_2","first-page":"3604","article-title":"Identification and characterization of a novel JAK2 tyrosine kinase inhibitor [abstract]","volume":"108","author":"Sayyah J","year":"2006","journal-title":"ASH Annual Meeting Abstracts. Blood"},{"key":"e_1_2_9_77_2","first-page":"3741","article-title":"EXEL\u20108232 a small molecule JAK2 inhibitor effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative disease induced by MPLW515L [abstract]","volume":"112","author":"Wernig G","year":"2008","journal-title":"ASH Annual Meeting Abstracts. Blood"},{"key":"e_1_2_9_78_2","first-page":"3549","article-title":"Effects of a novel selective JAK2 inhibitor AZ60 on STAT5 signaling and cellular growth in JAK2 V617F cell lines [abstract]","volume":"110","author":"Gozgit J","year":"2007","journal-title":"ASH Annual Meeting Abstracts. Blood"},{"key":"e_1_2_9_79_2","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1182\/blood.V108.11.2680.2680","article-title":"TG101209 a selective JAK2 kinase inhibitor suppresses endogenous and cytokine supported colony formation from hematopoietic progenitors carrying JAK2V617F or MPLW515K\/L mutations [abstract]","volume":"108","author":"Pardanani A","year":"2006","journal-title":"Blood"},{"key":"e_1_2_9_80_2","first-page":"3537","article-title":"AT9283, a potent inhibitor of JAK2, is active in JAK2 V617F myeloproliferative disease models [abstract]","volume":"110","author":"Squires MS","year":"2007","journal-title":"ASH Annual Meeting Abstracts. Blood"},{"key":"e_1_2_9_81_2","first-page":"856","article-title":"Effects of CYT387, a potent novel JAK2 inhibitor on JAK2\u2010V617F induced MPD [abstract]","volume":"112","author":"Bumm T","year":"2008","journal-title":"ASH Annual Meeting Abstracts. Blood"},{"key":"e_1_2_9_82_2","first-page":"3721","article-title":"In vitro and in vivo inhibition of JAK2 signaling by potent and selective JAK2 inhibitor [abstract]","volume":"112","author":"Markovtsov V","year":"2008","journal-title":"ASH Annual Meeting Abstracts. Blood"},{"key":"e_1_2_9_83_2","first-page":"3897","article-title":"Efficacy of R723, a potent and selective JAK2 inhibitor, in JAK2V617F\u2010induced murine MPD model [abstract]. ASH Annual Meeting Abstracts","volume":"114","author":"Shide K","year":"2009","journal-title":"Markovtsov"},{"key":"e_1_2_9_84_2","first-page":"3544","article-title":"The JAK2 kinase inhibitor LS104 induces growth arrest and apoptosis in JAK2V617F positive cells [abstract]","volume":"110","author":"Lipka D","year":"2007","journal-title":"ASH Annual Meeting Abstracts. Blood"},{"key":"e_1_2_9_85_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810069"},{"key":"e_1_2_9_86_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature08448"},{"key":"e_1_2_9_87_2","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood.V110.11.555.555","article-title":"Selective targeting of the JAK2V617F mutation in polycythemia vera and essential thrombocythemia by ITF2357, a novel histone deacetylase inhibitor [abstract]. ASH Annual Meeting Abstracts","volume":"110","author":"Guerini V","year":"2007","journal-title":"Blood"},{"key":"e_1_2_9_88_2","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1182\/blood.V112.11.100.100","article-title":"A phase 2A study of the histone deacetylase inhibitor ITF2357 in patients with JAK2V617F positive chronic myeloproliferative neoplasms [abstract]. ASH Annual Meeting Abstracts","volume":"112","author":"Rambaldi A","year":"2008","journal-title":"Blood"},{"key":"e_1_2_9_89_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-143537"},{"key":"e_1_2_9_90_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.6075"},{"key":"e_1_2_9_91_2","doi-asserted-by":"publisher","DOI":"10.4065\/79.7.883"},{"key":"e_1_2_9_92_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.160"},{"key":"e_1_2_9_93_2","first-page":"1027","article-title":"Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: a prospective, randomized, double\u2010blind, multicenter study","volume":"91","author":"Abgrall J\u2010F","year":"2006","journal-title":"Haematologica."},{"key":"e_1_2_9_94_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21827"},{"key":"e_1_2_9_95_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-02-004572"},{"key":"e_1_2_9_96_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.6548"},{"key":"e_1_2_9_97_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-009746"},{"key":"e_1_2_9_98_2","first-page":"2911","article-title":"Phase 1\/2 dose finding study of pomalidomide in myelofibrosis [abstract]","volume":"114","author":"Mesa RA","year":"2009","journal-title":"ASH Annual Meeting Abstracts. Blood"},{"key":"e_1_2_9_99_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.7356"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.25672","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.25672","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T18:33:38Z","timestamp":1760294018000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.25672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,4]]},"references-count":98,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,2,15]]}},"alternative-id":["10.1002\/cncr.25672"],"URL":"https:\/\/doi.org\/10.1002\/cncr.25672","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"subject":[],"published":{"date-parts":[[2010,10,4]]}}}